⌘K
Loading ticker…
IDEAYA Biosciences, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, IDEAYA Biosciences, Inc. Common Stock (IDYA) has a 3-month relative strength percentile of 64 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 58. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.6%, relative volume 2.58×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
64 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
IDYA is in a stage 3 topping pattern, week 9. Currently in a 117-day base; basing ADR 4.8% (broad 4.6%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 22.0% / 16.7%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
IDYA is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $89M notional. Top 3 carry $212M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $89M |
| IWMiShares Russell 2000 ETF | 0.10% | $69M |
| XBIState Street SPDR S&P Biotech ETF | 0.73% | $54M |
| VXFVanguard Extended Market ETF | 0.04% | $33M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $4M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IDYA Jan avg: 0.98% median: -5.76% win: 25% σ: 14.26% n: 4 2022-04-12 → 2026-05-29 | IDYA Feb avg: -2.29% median: 1.36% win: 75% σ: 8.95% n: 4 2022-04-12 → 2026-05-29 | IDYA Mar avg: -10.23% median: -11.10% win: 25% σ: 12.97% n: 4 2022-04-12 → 2026-05-29 | IDYA Apr avg: 4.96% median: -7.36% win: 40% σ: 21.37% n: 5 2022-04-12 → 2026-05-29 | IDYA May avg: 6.27% median: 1.27% win: 60% σ: 14.16% n: 5 2022-04-12 → 2026-05-29 | IDYA Jun avg: 7.10% median: 4.29% win: 75% σ: 11.82% n: 4 2022-04-12 → 2026-05-29 (current) | IDYA Jul avg: 10.43% median: 11.98% win: 75% σ: 11.78% n: 4 2022-04-12 → 2026-05-29 | IDYA Aug avg: -2.56% median: -3.71% win: 50% σ: 27.00% n: 4 2022-04-12 → 2026-05-29 | IDYA Sep avg: 8.68% median: 1.36% win: 50% σ: 31.39% n: 4 2022-04-12 → 2026-05-29 | IDYA Oct avg: 4.96% median: 6.95% win: 75% σ: 12.81% n: 4 2022-04-12 → 2026-05-29 | IDYA Nov avg: 7.65% median: 8.83% win: 75% σ: 8.07% n: 4 2022-04-12 → 2026-05-29 | IDYA Dec avg: 1.44% median: -0.66% win: 50% σ: 8.41% n: 4 2022-04-12 → 2026-05-29 |